+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Nitric oxide releasing acridone carboxamide derivatives as reverters of doxorubicin resistance in MCF7/Dx cancer cells

Nitric oxide releasing acridone carboxamide derivatives as reverters of doxorubicin resistance in MCF7/Dx cancer cells

Bioorganic Chemistry 64: 51-58

A series of nitric oxide donating acridone derivatives are synthesized and evaluated for in vitro cytotoxic activity against different sensitive and resistant cancer cell lines MCF7/Wt, MCF7/Mr (BCRP overexpression) and MCF7/Dx (P-gp expression). The results showed that NO-donating acridones are potent against both the sensitive and resistant cells. Structure activity relationship indicate that the nitric oxide donating moiety connected through a butyl chain at N(10) position as well as morpholino moiety linkage through an amide bridge on the acridone ring system at C-2 position, are required to exert a good cytotoxic effect. Further, good correlations were observed when cytotoxic properties were compared with in vitro nitric oxide release rate, nitric oxide donating group potentiated the cytotoxic effect of the acridone derivatives. Exogenous release of nitric oxide by NO donating acridones enhanced the accumulation of doxorubicin in MCF7/Dx cell lines when it was coadministered with doxorubicin, which inhibited the efflux process of doxorubicin. In summary, a nitric oxide donating group can potentiate the anti-MDR property of acridones.

(PDF emailed within 0-6 h: $19.90)

Accession: 058409735

Download citation: RISBibTeXText

PMID: 26657603

DOI: 10.1016/j.bioorg.2015.11.007

Related references

Treatment of doxorubicin-resistant MCF7/Dx cells with nitric oxide causes histone glutathionylation and reversal of drug resistance. Biochemical Journal 440(2): 175-183, 2012

Immunoglobulin G from breast cancer patients in stage I stimulates muscarinic acetylcholine receptors in MCF7 cells and induces proliferation. Participation of nitric oxide synthase-derived nitric oxide. Journal of Clinical Immunology 30(3): 474-484, 2010

Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Research 65(2): 516-525, 2005

Differential effects of doxorubicin and docetaxel on nitric oxide production and inducible nitric oxide synthase expression in MCF-7 human breast cancer cells. Oncology Research 14(7-8): 381-386, 2004

Treatment of human breast cancer cells with nitric oxide mimetics prevents acquisition of hypoxia-induced resistance to doxorubicin. Proceedings of the American Association for Cancer Research Annual Meeting 42: 814-815, March, 2001

Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells. Journal of Surgical Research 147(2): 240-246, 2008

Anti-calmodulin acridone derivatives modulate vinblastine resistance in multidrug resistant (MDR) cancer cells. European Journal of Medicinal Chemistry 39(2): 161-177, 2004

The effectiveness of oracin in enhancing the cytotoxicity of doxorubicin through the inhibition of doxorubicin deactivation in breast cancer MCF7 cells. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 40(10): 681-690, 2011

Nebivolol, a nitric oxide releasing beta-adrenergic antagonist and NCX 4016, a nitric oxide releasing aspirin derivative inhibit proliferation of cultured rat aortic smooth muscle cells. Nitric Oxide 4(3): 182-183, 2000

Novel nitric oxide-releasing derivatives of brusatol as anti-inflammatory agents: design, synthesis, biological evaluation, and nitric oxide release studies. Journal of Medicinal Chemistry 57(18): 7600-7612, 2014

Synthesis and evaluation of furoxan-based nitric oxide-releasing derivatives of tetrahydroisoquinoline as anticancer and multidrug resistance reversal agents. Bioorganic and Medicinal Chemistry Letters 21(19): 5934-5938, 2012

Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells. Breast Cancer Research and Treatment 96(2): 169-176, 2005

Doxorubicin inhibits the production of nitric oxide by colorectal cancer cells. Archives of Pharmacal Research (Seoul) 25(5): 691-696, October, 2002

Synthesis and preliminary biologic activity evaluation of nitric oxide-releasing andrographolide derivatives in RIN-m cells. Chemical and Pharmaceutical Bulletin 62(6): 519-523, 2015

Synthesis and evaluation of nitric oxide-releasing DDB derivatives as potential Pgp-mediated MDR reversal agents in MCF-7/Adr cells. Bioorganic and Medicinal Chemistry Letters 22(2): 801-805, 2012